GSK3β is involved in serotonin deficiency-related aberrant behaviour, since its inhibition alleviates such behaviour [169], while it plays a part in dopamine-mediated hyperlocomotion, an effect which is blocked by anti-psychotic treatment [170]; the interplay between these neuro-transmitters could prove to be crucial in schizophrenia [171, 172], and many psychiatric treatments active in schizophrenia target both monoamine neurotransmission and GSK3 [173]. The gene discussed is GSK3B; the disease is schizophrenia.